Because p53 acts as a tetramer, these p53 mutants also have been characterized as having dominant-negative effects on any activity of the remaining wild type p53 in cancer cells (Aubrey et al, 2018; Gencel-Augusto and Lozano, 2020). The gene discussed is TP53; the disease is cancer.